Author: philnae

HeartForce is proud to announce that it has successfully completed the entire data collection process in Uzbekistan consisting of: (1) patients with high levels of coronary artery disease (Stenosis of ≥ 50% in at least one coronary artery), (2) a healthy and age-matched control group and (3) patients with mild to medium levels of occlusion… Continue reading Fifth HeartForce Update on the CardioClin Multi-Center Study in Uzbekistan

HeartForce has successfully filed a continuation application at the United States Patent and Trademark Office on November 21, 2022: “Sensor apparatuses, methods of operating same and systems including same and methods and systems for sensing and analyzing electromechanical characteristics of a heart” In accordance with our instructions, the continuation application was assigned application number 17/991,523.… Continue reading HeartForce files Continuation of United States Patent Application

HeartForce’s scientific team in Uzbekistan has collected in-depth data for developing an algorithm to screen for coronary artery disease (CAD). The study has been divided into three phases. In phase 1, we collected a total of 1,530 patients’ data to investigate the ability to use machine learning algorithms to predict the presence of CAD. Most… Continue reading Fourth HeartForce Update on the Cardio Clin Multi-Center Study in Uzbekistan

The objective of our study is to enhance the accuracy of the Q-wave detection to handle abnormal ECG signal patterns more accurately. Q-wave detection is a significant factor for segmenting the cardiac vibrational signal for coronary artery disease (CAD) detection. By identifying the abnormal ECG signal segment (e.g., caused by Afib, premature contraction, movement artifacts,… Continue reading HeartForce Commences Automatic Improvement of ECG Processing Methods

In spring of 2022, our development team updated the design of our CardioClin for improved user ergonomics. The new design has an inverted heart shape which is attached to the sternum using a standard ECG adhesive electrode. It has two ports for the “right-arm” and “left-leg” ECG leads. A light indicator is located on the… Continue reading HeartForce Introduces CardioClin 2.0

As reported in November of 2021, HeartForce has successfully completed the data collection of 1500 patients, suspected of having coronary artery disease (CAD), in the clinical trial in Uzbekistan. The dataset consisted of the following two datasets: Tashkent Patients and Karshi Patients Tashkent Control Group The first data set consisted of patients that were suspected… Continue reading Third HeartForce Update on the CardioClin Multi-Center Study in Uzbekistan